RWD161 Therapeutic Drug Monitoring (TDM) of Infliximab Is Associated with Lower Biologic Switch Expenditures Compared to No-TDM Cohort of IBD Patients Based on 12 to 48-Month Real-World Outcomes from a US Community GI Practice
Abstract
Authors
A Shim K Young A Sabban R Eisdorfer S Rosenberg